Drugs / mechlorethamine
mechlorethamine
also known as
Mechlorethamine Hydrochloride · chlormethine · Valchlor · MCH · Nitrogen Mustard · Chlorethazine · Chlormethine hcl · Chlormethine Hydrochloride · +11 more
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Ledaga | — | 2017-03-03 | europa.eu ↗ |
| Approved | US (FDA) | MUSTARGEN | — | 1949-03-15 | fda.gov ↗ |
Trials 16 · a red edge is where a trial was stopped
1947194819491950195119521953195419551956195719581959196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04026269 | Jul 2019 → Dec 2020 | classic Hodgkin lymphoma | Han weidong | Unknown | No outcome recorded |
| Phase 212 trials | ||||||
| Phase 2 | NCT04218825 | Mar 2022 → Apr 2023 | mycosis fungoides | European Organisation for Research and Treatment of Cancer - EORTC | Terminated | No outcome recorded |
| Phase 2 | NCT03288818 | Aug 2018 → Dec 2020 | mycosis fungoides | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Withdrawn | No outcome recorded |
| Phase 2 | NCT03417141 | Apr 2018 → Aug 2019 | lichen planopilaris | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT03380026 | Dec 2017 → Aug 2020 | folliculotropic mycosis fungoides, granulomatous slack skin disease, mycosis fungoides | Rochester Skin Lymphoma Medical Group, PLLC | Completed | No outcome recorded |
| Phase 2 | NCT02881749 | Sep 2016 → Aug 2020 | mycosis fungoides | Thomas Jefferson University | Unknown | No outcome recorded |
| Phase 2 | NCT00846742 | Jun 2009 → Jan 2019 overdue | Hodgkins lymphoma | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT00574496 | Nov 2007 → Aug 2022 | lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00535470 | Jul 2007 → Mar 2011 | mycosis fungoides | Yaupon Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00003262 | May 1997 → ? | lymphoma | Centro di Riferimento Oncologico - Aviano | Unknown | No outcome recorded |
| Phase 2 | NCT00002714 | Apr 1995 → Sep 2001 | lymphoma | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT00002715 | Apr 1989 → Jan 2007 | lymphoma | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT00002463 | Feb 1989 → Jan 2007 | central nervous system neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT00041210 | Oct 2001 → ? | lymphoma | Mount Vernon Cancer Centre at Mount Vernon Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT00379041 | Sep 1993 → Oct 1998 overdue | lymphoma | European Organisation for Research and Treatment of Cancer - EORTC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00002462 | Sep 1989 → May 2000 overdue | lymphoma | European Organisation for Research and Treatment of Cancer - EORTC | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 7 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02968446 Background | Nov 2016 → Oct 2018 | dermatitis | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06149247 Comparator | Dec 2023 → May 2024 | mycosis fungoides | Soligenix | Completed | No outcome recorded |
| Phase 2 | NCT00352027 Background | Jul 2006 → May 2015 | Hodgkins lymphoma | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00168064 Comparator | May 2006 → Aug 2010 | mycosis fungoides | Yaupon Therapeutics | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00003389 Comparator | Jun 1999 → Sep 2011 | lymphoma | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05106192 Background | Apr 2022 → Jun 2025 | anaplastic large cell lymphoma, follicular lymphoma, lymphomatoid papulosis, mycosis fungoides | Case Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| — | NCT05303480 Comparator | Dec 2021 → Dec 2022 | mycosis fungoides | Centre for Human Drug Research, Netherlands | Completed | No outcome recorded |
Evidence & citations 22 cited values
Every value below carries the sentence it was read from. 25 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mechlorethamine | “mechlorethamine hydrochloride IV on day 1 of weeks 1 and 5” NCT00846742 ↗ |
| Known as | Chlorethazine | ChEMBL registry synonym — accepted as the source's own label CHEMBL427 ↗ |
| Known as | chlormethine | “Chlormethine Hydrochloride Injection 10mg d1,8 iv” NCT04026269 ↗ |
| Known as | Chlormethine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL427 ↗ |
| Known as | Chlormethine Hydrochloride | “Chlormethine Hydrochloride Injection 10mg d1,8 iv” NCT04026269 ↗ |
| Known as | Chlormethini hydrochloridum | ChEMBL registry synonym — accepted as the source's own label CHEMBL427 ↗ |
| Known as | Clormetina | ChEMBL registry synonym — accepted as the source's own label CHEMBL427 ↗ |
| Known as | Ledaga | ChEMBL registry synonym — accepted as the source's own label CHEMBL427 ↗ |
| Known as | MCH | “Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation” NCT00535470 ↗1“mechlorethamine-MCH (nitrogen mustard)” NCT00168064 ↗ |
| Known as | Mechlorethamine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL427 ↗ |
| Known as | Mechlorethamine Hydrochloride | “To evaluate the efficacy and safety of a novel mechlorethamine hydrochloride, 0.02%, gel in mycosis fungoides.” PMID 23069814 ↗ Jan 20133“Drug: Mechlorethamine Hydrochloride” NCT00002463 ↗ “Drug: Mechlorethamine hydrochloride” NCT00002715 ↗ |
| Known as | Mechlorethamine Hydrochloride Gel | “Mechlorethamine hydrochloride gel (Valchlor) regimen” NCT03288818 ↗ |
| Known as | Mustargen | ChEMBL registry synonym — accepted as the source's own label CHEMBL427 ↗ |
| Known as | Nitrogen Mustard | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05106192 ↗ |
| Known as | Nitrogen mustard (hn 2) | ChEMBL registry synonym — accepted as the source's own label CHEMBL427 ↗ |
| Known as | NSC-10107 | ChEMBL registry synonym — accepted as the source's own label CHEMBL427 ↗ |
| Known as | NSC-128663 | ChEMBL registry synonym — accepted as the source's own label CHEMBL427 ↗ |
| Known as | NSC-757087 | ChEMBL registry synonym — accepted as the source's own label CHEMBL427 ↗ |
| Known as | NSC-762 | “Mechlorethamine, NM, NSC-762” NCT00002462 ↗ |
| Known as | Valchlor | “Valchlor, a 0.016% gel formulation of mechlorethamine.” NCT03417141 ↗ |
| Modality | Small molecule | — CHEMBL427 ↗ |
| Route | Intravenous | “mechlorethamine IV and vincristine IV on days 1 and 8” NCT00002463 ↗ |